Efficacy and Safety of Landiolol in Patients With Ventricular Tachyarrhythmias With or Without Renal Impairment　― Subanalysis of the J-Land II Study ―-Reference-Cited by-同舟云学术

Efficacy and Safety of Landiolol in Patients With Ventricular Tachyarrhythmias With or Without Renal Impairment　― Subanalysis of the J-Land II Study ―

Published:2020-08-07 Issue:8 Volume:2 Page:440-445
ISSN:2434-0790
Container-title:Circulation Reports
language:en
Short-container-title:Circ Rep

Author:

Shiga Tsuyoshi¹,Ikeda Takanori²,Shimizu Wataru³,Kinugawa Koichiro⁴,Sakamoto Atsuhiro⁵,Nagai Ryozo⁶,Daimon Takashi⁷,Oki Kaori⁸,Okamoto Haruka⁹,Yamashita Takeshi¹⁰

Affiliation:

1. Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine

2. Department of Cardiovascular Medicine, Toho University Faculty of Medicine

3. Department of Cardiovascular Medicine, Nippon Medical School

4. Internal Medicine (2), Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama

5. Department of Anesthesiology, Nippon Medical School

6. Jichi Medical University

7. Department of Biostatistics, Hyogo College of Medicine

8. Early Clinical Development Planning II, Ono Pharmaceutical Co. Ltd

9. Clinical Operation Division I, Ono Pharmaceutical Co. Ltd

10. The Cardiovascular Institute

Publisher

Japanese Circulation Society

Subject

Marketing,Organizational Behavior and Human Resource Management,Strategy and Management,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/circrep/2/8/2_CR-20-0017/_pdf

Reference13 articles.

1. 1. Cleveland Clinic. Sudden cardiac death (sudden cardiac arrest). https://my.clevelandclinic.org/health/diseases/17522-sudden-cardiac-death-sudden-cardiac-arrest (accessed June 11, 2020).

2. 2. Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA, et al. Chronic kidney disease and arrhythmias: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Eur Heart J 2018; 39: 2314–2325.

3. 3. Wan C, Herzog CA, Zareba W, Szymkiewicz SJ. Sudden cardiac arrest in hemodialysis patients with wearable cardioverter defibrillator. Ann Noninvasive Electrocardiol 2014; 19: 247–257.

4. 4. Takahashi A, Shiga T, Shoda M, Manaka T, Ejima K, Hagiwara N. Impact of renal dysfunction on appropriate therapy in implantable cardioverter defibrillator patients with non-ischaemic dilated cardiomyopathy. Europace 2009; 11: 1476–1482.

5. 5. Myoishi M, Yasuda S, Miyazaki S, Ueno K, Morii I, Satomi K, et al. Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis. Circ J 2003; 67: 898–900.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal use of intravenous landiolol in acute cardiac care;Expert Review of Cardiovascular Therapy;2023-11-02

2. 2022 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and Prevention of Sudden Cardiac Death developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) with the patronage of the Association for European Pediatric and Congenital Cardiology (AEPC);G ITAL CARDIOL;2023

3. Emergency Management of Electrical Storm: A Practical Overview;Medicina;2023-02-19

4. Hemodynamic and Rhythmologic Effects of Push-Dose Landiolol in Critical Care—A Retrospective Cross-Sectional Study;Pharmaceuticals;2023-01-17

5. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death;European Heart Journal;2022-08-26